AI in Pathology Market by Neural Network, Function, Use Case, End User, & Region - Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 STUDY ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
  • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.5.2 SCOPE-RELATED LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AI IN PATHOLOGY MARKET OVERVIEW
• 4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX
• 4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER & COUNTRY
• 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Development of CNNs and advanced AI models
    • 5.2.1.2 Integration of AI into multiplex imaging
    • 5.2.1.3 Increasing cases of misdiagnoses in patients
    • 5.2.1.4 Benefits of AI-augmented telepathology
    • 5.2.1.5 Advancements in deep learning & image processing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of digital pathology systems
    • 5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software
    • 5.2.2.3 Inadequate interoperability issues with legacy systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing demand for personalized medicine
    • 5.2.3.2 Integration of multi-omics data
    • 5.2.3.3 Predictive analytics for disease progression
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Insufficient data for AI algorithms
    • 5.2.4.2 Data privacy & ethical concerns
    • 5.2.4.3 Challenges associated with interpretability of AI models
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 INDUSTRY TRENDS
  • 5.4.1 EVOLUTION OF AI IN PATHOLOGY
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Machine learning and artificial intelligence
    • 5.7.1.2 Computer vision
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Cloud computing
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Telepathology
• 5.8 REGULATORY ANALYSIS
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATORY LANDSCAPE
    • 5.8.2.1 North America
      • 5.8.2.1.1 US
      • 5.8.2.1.2 Canada
    • 5.8.2.2 Europe
    • 5.8.2.3 Asia Pacific
      • 5.8.2.3.1 Japan
      • 5.8.2.3.2 China
• 5.9 PRICING ANALYSIS
  • 5.9.1 INDICATIVE PRICING ANALYSIS, BY OFFERING
  • 5.9.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 THREAT OF NEW ENTRANTS
  • 5.10.2 THREAT OF SUBSTITUTES
  • 5.10.3 BARGAINING POWER OF SUPPLIERS
  • 5.10.4 BARGAINING POWER OF BUYERS
  • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
  • 5.11.2 JURISDICTION & TOP APPLICANT ANALYSIS
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 END-USER ANALYSIS
  • 5.13.1 UNMET NEEDS OF END USERS
  • 5.13.2 END-USER EXPECTATIONS
• 5.14 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 CASE STUDY 1: PATHAI USES PYTORCH TO IMPROVE PATIENT OUTCOMES WITH AI-POWERED PATHOLOGY
  • 5.15.2 CASE STUDY 2: COMBATING CERVICAL CANCER WITH AI
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 AI IN PATHOLOGY MARKET: BUSINESS MODELS
• 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
  • 5.18.1 KEY USE CASES
  • 5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    • 5.18.2.1 Case Study: Accelerated biomarker discovery and clinical trial optimization
  • 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.18.3.1 Drug discovery & development market
    • 5.18.3.2 Medical imaging & diagnostics market
  • 5.18.4 USERS READINESS AND IMPACT ASSESSMENT
    • 5.18.4.1 User readiness
      • 5.18.4.1.1 Pharmaceutical companies
      • 5.18.4.1.2 Biopharmaceutical companies
    • 5.18.4.2 Impact assessment
      • 5.18.4.2.1 User A: Pharmaceutical companies
        • 5.18.4.2.1.1 Implementation
        • 5.18.4.2.1.2 Impact
      • 5.18.4.2.2 User B: Biopharmaceutical companies
        • 5.18.4.2.2.1 Implementation
        • 5.18.4.2.2.2 Impact
• 5.19 TRADE ANALYSIS
  • 5.19.1 IMPORT DATA
  • 5.19.2 EXPORT DATA

6 AI IN PATHOLOGY MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 END-TO-END SOLUTIONS
  • 6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
• 6.3 NICHE POINT SOLUTIONS
  • 6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
• 6.4 TECHNOLOGY
  • 6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL UPTAKE
• 6.5 HARDWARE
• 6.6 MICROSCOPES
  • 6.6.1 AUTOMATED ANALYSIS OF TISSUE SAMPLES FOR EFFECTIVE CONCLUSIONS TO FUEL UPTAKE
• 6.7 SCANNERS
  • 6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
• 6.8 STORAGE SYSTEMS
  • 6.8.1 ABILITY TO PROVIDE STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH

7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK

• 7.1 INTRODUCTION
• 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS)
  • 7.2.1 ABILITY TO PROVIDE HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
• 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS)
  • 7.3.1 DESIGNED FOR GENERATION OF ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
• 7.4 RECURRENT NEURAL NETWORKS (RNNS)
  • 7.4.1 ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL UPTAKE
• 7.5 OTHER NEURAL NETWORKS

8 AI IN PATHOLOGY MARKET, BY FUNCTION

• 8.1 INTRODUCTION
• 8.2 IMAGE ANALYSIS
  • 8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
• 8.3 DIAGNOSTICS
  • 8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
• 8.4 WORKFLOW MANAGEMENT
  • 8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
• 8.5 DATA MANAGEMENT
  • 8.5.1 ADVANCEMENTS IN DATA INTEGRATION & PROCESSING TO BOOST DEMAND
• 8.6 PREDICTIVE ANALYTICS
  • 8.6.1 GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
• 8.7 CDSS
  • 8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
• 8.8 AUTOMATED REPORT GENERATION
  • 8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
• 8.9 QUALITY ASSURANCE TOOLS
  • 8.9.1 RISING REGULATORY DEMANDS TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS

9 AI IN PATHOLOGY MARKET, BY USE CASE

• 9.1 INTRODUCTION
• 9.2 DRUG DISCOVERY
  • 9.2.1 TARGET IDENTIFICATION & SELECTION
    • 9.2.1.1 Analysis of molecular & histological data for biomarker discovery to fuel market
  • 9.2.2 TARGET VALIDATION
    • 9.2.2.1 Increasing demand for precision medicine to drive market
  • 9.2.3 HIT IDENTIFICATION & PRIORITIZATION
    • 9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake
  • 9.2.4 HIT-TO-LEAD IDENTIFICATION
    • 9.2.4.1 Advancements in ML to support market growth
  • 9.2.5 LEAD OPTIMIZATION
    • 9.2.5.1 Growing focus on therapeutic efficacy to propel market
  • 9.2.6 CANDIDATE SELECTION & VALIDATION
    • 9.2.6.1 Critical requirement for regulatory approvals to drive market
• 9.3 DISEASE DIAGNOSIS & PROGNOSIS
  • 9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
• 9.4 CLINICAL WORKFLOW
  • 9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
• 9.5 TRAINING & EDUCATION
  • 9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH

10 AI IN PATHOLOGY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
• 10.3 HOSPITALS & REFERENCE LABORATORIES
  • 10.3.1 INCREASING UPTAKE OF INFECTIOUS DISEASE DIAGNOSIS TO DRIVE MARKET
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 INCREASING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT MARKET GROWTH

11 AI IN PATHOLOGY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 UK
    • 11.3.2.1 Increasing focus on drug discovery & development to boost demand
  • 11.3.3 GERMANY
    • 11.3.3.1 Availability of funding for AI initiatives to fuel uptake
  • 11.3.4 FRANCE
    • 11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake
  • 11.3.5 ITALY
    • 11.3.5.1 Digital transformation and innovation in healthcare to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Workforce shortages to fuel market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing incidence of infectious & chronic diseases to fuel uptake
  • 11.4.3 JAPAN
    • 11.4.3.1 Advanced healthcare infrastructure to propel market
  • 11.4.4 INDIA
    • 11.4.4.1 Growing focus on healthcare digitization to boost demand
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Strategic investments for AI adoption to support market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Growth in pharmaceutical R&D to drive market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Increasing investments in expansion of technological expertise to support market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Offering footprint
    • 12.5.5.3 Use-case footprint
    • 12.5.5.4 End-user footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS /SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 COMPANY VALUATION
  • 12.7.2 FINANCIAL METRICS
  • 12.7.3 BRAND/SOFTWARE COMPARISON ANALYSIS
• 12.8 COMPETITIVE SCENARIO
  • 12.8.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 12.8.2 DEALS
  • 12.8.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 KONINKLIJKE PHILIPS N.V.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 MnM view
      • 13.1.1.3.1 Key strengths
      • 13.1.1.3.2 Strategic choices
      • 13.1.1.3.3 Weaknesses & competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 HOLOGIC, INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product/Service approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 AKOYA BIOSCIENCES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 AIFORIA TECHNOLOGIES PLC
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 INDICA LABS INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches & approvals
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
  • 13.1.7 OPTRASCAN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Other developments
  • 13.1.8 IBEX MEDICAL ANALYTICS LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product/Service launches & approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 MINDPEAK GMBH
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product/Service approvals
      • 13.1.9.3.2 Deals
      • 13.1.9.3.3 Other developments
  • 13.1.10 TRIBUN HEALTH
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 TECHCYTE, INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product/Service launches
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Other developments
  • 13.1.12 DEEP BIO INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 LUMEA INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 VISIOPHARM
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services offered
      • 13.1.14.2.1 Recent developments
      • 13.1.14.2.2 Product/Service launches
      • 13.1.14.2.3 Expansions
  • 13.1.15 AETHERAI
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
  • 13.1.16 AIOSYN
    • 13.1.16.1 Business overview
    • 13.1.16.2 Product/Services offered
      • 13.1.16.2.1 Product/Service launches
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Deals
    • 13.1.16.4 Recent developments
      • 13.1.16.4.1 Other developments
  • 13.1.17 PAIGE AI, INC.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products/Services offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Product/Service launches & approvals
      • 13.1.17.3.2 Deals
      • 13.1.17.3.3 Other developments
  • 13.1.18 PROSCIA, INC.
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products/Services offered
    • 13.1.18.3 Recent developments
      • 13.1.18.3.1 Product/Service launches & enhancements
      • 13.1.18.3.2 Deals
      • 13.1.18.3.3 Other developments
  • 13.1.19 PATHAI, INC.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products/Services offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Product/Service launches & approvals
      • 13.1.19.3.2 Deals
  • 13.1.20 TEMPUS LABS, INC.
    • 13.1.20.1 Business overview
    • 13.1.20.2 Products/Services offered
    • 13.1.20.3 Recent developments
      • 13.1.20.3.1 Product/Service launches
• 13.2 OTHER PLAYERS
  • 13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD.
  • 13.2.2 DOMORE DIAGNOSTICS AS
  • 13.2.3 VERILY LIFE SCIENCES, LLC
  • 13.2.4 DEEPPATH
  • 13.2.5 4D PATH INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
• TABLE 2 STUDY ASSUMPTION ANALYSIS
• TABLE 3 RISK ASSESSMENT ANALYSIS
• TABLE 4 AI IN PATHOLOGY MARKET: ROLE IN ECOSYSTEM
• TABLE 5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION
• TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
• TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
• TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES
• TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
• TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
• TABLE 12 INDICATIVE PRICING ANALYSIS, BY OFFERING
• TABLE 13 AI IN PATHOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS (%)
• TABLE 15 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS
• TABLE 16 UNMET NEEDS FOR AI IN PATHOLOGY MARKET
• TABLE 17 END-USER EXPECTATIONS FOR AI IN PATHOLOGY MARKET
• TABLE 18 AI IN PATHOLOGY MARKET: LIST OF CONFERENCES AND EVENTS
• TABLE 19 IMPORT DATA FOR HS CODE 9011, BY COUNTRY, 2020-2022 (USD THOUSAND)
• TABLE 20 EXPORT DATA FOR HS CODE 9011, BY COUNTRY, 2020-2022 (USD THOUSAND)
• TABLE 21 AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 22 AI IN PATHOLOGY MARKET FOR OFFERING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 23 AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 24 AI IN PATHOLOGY MARKET FOR NICHE-POINT SOLUTIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 25 AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 26 AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 27 AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 28 AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 29 AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 30 AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 31 AI IN PATHOLOGY MARKET, BY NEURAL NETWORKS, 2022-2029 (USD MILLION)
• TABLE 32 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 33 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 34 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 35 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 36 AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 37 AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 38 AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 39 AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 40 AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 41 AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 42 AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 43 AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 44 AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 45 AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 46 DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY
• TABLE 47 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 48 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 49 AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 50 AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 51 AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 52 AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 53 AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 54 AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 55 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 56 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 57 AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 58 AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 59 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 60 AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 61 AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 62 AI IN PATHOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 63 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 64 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 65 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 66 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 67 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 68 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 69 US: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 70 US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 71 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 72 US: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 73 US: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 74 CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 75 CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 76 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 77 CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 78 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 79 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 80 EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 81 EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 82 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 83 EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 84 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 85 UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 86 UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 87 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 88 UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 89 UK: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 90 GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 91 GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 92 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 93 GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 94 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 95 FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 96 FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 97 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 98 FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 99 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 100 ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 101 ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 102 ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 103 ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 104 ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 105 SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 106 SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 107 SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 108 SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 109 SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 110 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 111 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 112 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 113 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 114 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 115 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 116 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 117 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 118 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 119 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 120 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 121 CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 122 CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 123 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 124 CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 125 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 126 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
• TABLE 127 JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 128 JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 129 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 130 JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 131 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 132 INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 133 INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 134 INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 135 INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 136 INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 137 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 138 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 139 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 140 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 141 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 142 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 143 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 144 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 145 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 146 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 147 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 148 BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 149 BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 150 BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 151 BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 152 BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 153 MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 154 MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 155 MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 156 MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 157 MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 158 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 159 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 160 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 161 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 162 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 163 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 164 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 165 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 166 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 167 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 168 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 169 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 170 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 171 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 172 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 173 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 174 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 175 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
• TABLE 176 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
• TABLE 177 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
• TABLE 178 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 179 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
• TABLE 180 AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION
• TABLE 181 OFFERING FOOTPRINT ANALYSIS
• TABLE 182 USE-CASE FOOTPRINT ANALYSIS
• TABLE 183 END-USER FOOTPRINT ANALYSIS
• TABLE 184 REGION FOOTPRINT ANALYSIS
• TABLE 185 AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES
• TABLE 186 AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
• TABLE 187 AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
• TABLE 188 AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 189 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, 2021-2024
• TABLE 190 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
• TABLE 191 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED
• TABLE 192 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 193 F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 194 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 195 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 196 HOLOGIC, INC.: COMPANY OVERVIEW
• TABLE 197 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 198 HOLOGIC, INC.: PRODUCT/SERVICE APPROVALS, JANUARY 2021-OCTOBER 2024
• TABLE 199 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
• TABLE 200 AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED
• TABLE 201 AKOYA BIOSCIENCES INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 202 AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW
• TABLE 203 AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED
• TABLE 204 AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 205 INDICA LABS INC.: COMPANY OVERVIEW
• TABLE 206 INDICA LABS INC.: PRODUCTS/SERVICES OFFERED
• TABLE 207 INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
• TABLE 208 INDICA LABS INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 209 INDICA LABS INC.: EXPANSIONS, JANUARY 2021-OCTOBER 2024
• TABLE 210 OPTRASCAN: COMPANY OVERVIEW
• TABLE 211 OPTRASCAN: PRODUCTS/SERVICES OFFERED
• TABLE 212 OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 213 IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW
• TABLE 214 IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 215 IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES/APPROVALS, JANUARY 2021-OCTOBER 2024
• TABLE 216 IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 217 MINDPEAK GMBH: COMPANY OVERVIEW
• TABLE 218 MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED
• TABLE 219 MINDPEAK GMBH: PRODUCT/SERVICE APPROVALS, JANUARY 2021-OCTOBER 2024
• TABLE 220 MINDPEAK GMBH: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 221 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 222 TRIBUN HEALTH: COMPANY OVERVIEW
• TABLE 223 TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED
• TABLE 224 TRIBUN HEALTH: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 225 TECHCYTE, INC.: COMPANY OVERVIEW
• TABLE 226 TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 227 TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 228 TECHCYTE, INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 229 TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 230 DEEP BIO INC.: COMPANY OVERVIEW
• TABLE 231 DEEP BIO INC.: PRODUCTS/SERVICES OFFERED
• TABLE 232 DEEP BIO INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 233 LUMEA INC.: COMPANY OVERVIEW
• TABLE 234 LUMEA INC.: PRODUCTS/SERVICES OFFERED
• TABLE 235 LUMEA INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 236 VISIOPHARM: COMPANY OVERVIEW
• TABLE 237 VISIOPHARM: PRODUCTS/SERVICES OFFERED
• TABLE 238 VISIOPHARM: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 239 VISIOPHARM: EXPANSIONS, JANUARY 2021-OCTOBER 2024
• TABLE 240 AETHERAI: COMPANY OVERVIEW
• TABLE 241 AETHERAI: PRODUCTS/SERVICES OFFERED
• TABLE 242 AETHERAI: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 243 AIOSYN: COMPANY OVERVIEW
• TABLE 244 AIOSYN: PRODUCTS/SERVICES OFFERED
• TABLE 245 AIOSYN: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 246 AIOSYN: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 247 AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 248 PAIGE AI, INC.: COMPANY OVERVIEW
• TABLE 249 PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 250 PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
• TABLE 251 PAIGE AI, INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 252 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 253 PROSCIA, INC.: COMPANY OVERVIEW
• TABLE 254 PROSCIA, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 255 PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 256 PROSCIA, INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 257 PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 258 PATHAI, INC.: COMPANY OVERVIEW
• TABLE 259 PATHAI, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 260 PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
• TABLE 261 PATHAI, INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 262 TEMPUS LABS, INC.: COMPANY OVERVIEW
• TABLE 263 TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 264 TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-OCTOBER 2024
• TABLE 265 KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW
• TABLE 266 DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW
• TABLE 267 VERILY LIFE SCIENCES, LLC: COMPANY OVERVIEW
• TABLE 268 DEEPPATH: COMPANY OVERVIEW
• TABLE 269 4D PATH INC.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 RESEARCH DESIGN
• FIGURE 2 PRIMARY SOURCES
• FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
• FIGURE 5 AI IN PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION
• FIGURE 6 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN PATHOLOGY
• FIGURE 7 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024-2029)
• FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 9 TOP-DOWN APPROACH
• FIGURE 10 DATA TRIANGULATION METHODOLOGY
• FIGURE 11 AI IN PATHOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
• FIGURE 12 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 AI IN PATHOLOGY MARKET, BY USE CASE, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 AI IN PATHOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT
• FIGURE 16 DEVELOPMENT OF CNNS AND AI LEARNING MODELS TO PROPEL MARKET
• FIGURE 17 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
• FIGURE 19 US TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
• FIGURE 20 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 21 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES (SEPTEMBER 2024)
• FIGURE 22 AI IN PATHOLOGY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 23 ECOSYSTEM ANALYSIS
• FIGURE 24 VALUE CHAIN ANALYSIS
• FIGURE 25 EUROPE: IVDR TIMELINE
• FIGURE 26 THERE IS MODERATE-TO-HIGH COMPETITIVE INTENSITY AMONG MARKET PLAYERS
• FIGURE 27 NUMBER OF PATENTS PUBLISHED, JANUARY 2015-OCTOBER 2024
• FIGURE 28 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN PATHOLOGY PATENTS (JANUARY 2015 TO MAY 2024)
• FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS
• FIGURE 30 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS
• FIGURE 31 FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET
• FIGURE 32 MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY
• FIGURE 33 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT
• FIGURE 34 ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT
• FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS FOR AI IN PATHOLOGY MARKET, 2019-2023
• FIGURE 36 AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2023)
• FIGURE 37 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 38 AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT
• FIGURE 39 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF LIFE SCIENCE ANALYTICS VENDORS
• FIGURE 41 EV/EBITDA OF KEY VENDORS
• FIGURE 42 AI IN PATHOLOGY MARKET: BRAND/PRODUCT COMPARISON ANALYSIS
• FIGURE 43 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
• FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
• FIGURE 45 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 46 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 47 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2023)